Apitegromab + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Spinal Muscular Atrophy

Conditions

Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin

Trial Timeline

Apr 14, 2022 → Dec 18, 2024

NCT ID

NCT05156320

About Apitegromab + Placebo

Apitegromab + Placebo is a phase 3 stage product being developed by Scholar Rock Holding for Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT05156320. Target conditions include Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07435129	Phase 2	Recruiting	Aug 1, 2026	Dec 1, 2028	Facioscapulohumeral Muscular Dystrophy
NCT05156320	Phase 3	Completed	Apr 14, 2022	Dec 18, 2024	Spinal Muscular Atrophy

Competing Products

20 competing products in Spinal Muscular Atrophy

See all competitors

Product	Company	Stage	Hype Score
SUN13837 injection + Placebo	Daiichi Sankyo	Phase 2	52
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg	Astellas Pharma	Phase 2	52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells	Sun Pharmaceutical	Phase 2	52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells	Sun Pharmaceutical	Phase 1	33
Elezanumab	AbbVie	Pre-clinical	23
Elezanumab + Placebo	AbbVie	Phase 2	52
Ropivacaine + Bupivacaine	AstraZeneca	Phase 3	77
Onasemnogene Abeparvovec-xioi	Novartis	Phase 1	33
Zolgensma	Novartis	Pre-clinical	23
BVS857 + Placebo	Novartis	Phase 2	52
AVXS-101	Novartis	Phase 1	33
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	77
Onasemnogene Abeparvovec-brve	Novartis	Approved	85
Onasemnogene Abeparvovec-xioi	Novartis	Pre-clinical	23
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	77
branaplam	Novartis	Phase 1/2	41
Onasemnogene Abeparvovec-xioi	Novartis	Phase 3	77
onasemnogene abeparvovec	Novartis	Phase 3	77
onasemnogene abeparvovec-xioi	Novartis	Phase 3	77
Risdiplam	Roche	Phase 1	33

Other Products from Scholar Rock Holding

ApitegromabPhase 3

Apitegromab + PlaceboPhase 2

SRK-015Phase 2

Apitegromab + Nusinersen + RisdiplamPhase 2

Apitegromab + Placebo + TirzepatidePhase 2